Octreoteva Long Acting (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreoteva Long Acting, is a somatostatin analog presented as a long‑acting formulation for intramuscular, intravenous use. It is employed in the management of hormone‑secreting tumors and related endocrine disorders in adults.

GNH USA supplies Octreoteva Long Acting as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octreotide acetate is used in several endocrine‑related conditions where inhibition of hormone secretion is required. - Acromegaly: reduces excessive growth hormone production and helps control disease activity. - Neuroendocrine tumors: controls hormone‑related flushing and diarrhea associated with carcinoid syndrome. - VIPoma and other functional pancreatic tumors: decreases vasoactive intestinal peptide secretion and mitigates severe watery diarrhea.

Adverse reactions to Octreotide acetate may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal cramping, or pain. - Injection site reactions: erythema, swelling, or induration. - Gallbladder abnormalities: biliary sludge or gallstones. - Hyperglycaemia or hypoglycaemia: altered blood glucose levels. - Headache or dizziness.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas. - Severe hypersensitivity: anaphylaxis or severe skin reactions. - Cardiac arrhythmias: irregular heart rhythms. - Acute cholecystitis: inflammation of the gallbladder. - Severe hyperglycaemia requiring medical intervention.

Before initiating therapy with Octreotide acetate, clinicians should assess patient‑specific factors and monitor for potential complications. - Cardiovascular assessment: evaluate for pre‑existing arrhythmias or heart disease. - Glycaemic monitoring: check blood glucose regularly, especially in diabetic patients. - Gallbladder surveillance: perform periodic imaging to detect sludge or stones. - Drug interactions: review concomitant medications that affect glucose or cardiac function. - Pregnancy and lactation: weigh potential benefits against risks; use only if clearly needed. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide acetate can influence the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Insulin or oral hypoglycaics: may require dose adjustment due to altered glucose control. - Cytochrome P450 substrates metabolised by CYP3A4: risk of increased exposure.

Moderate Interactions (Monitor Closely): - Somatostatin analog‑containing regimens: additive hormonal suppression. - QT‑prolonging agents: potential for enhanced cardiac repolarisation effects. - Anticoagulants: monitor clotting parameters as gastrointestinal effects may alter absorption.